Navigation Links
Januvia Pancreatic Cancer Lawsuit: Bernstein Liebhard LLP Comments on Growing Litigation Surrounding Januvia
Date:7/14/2013

New York, New York (PRWEB) July 14, 2013

Januvia pancreatic cancer lawsuit claims, as well as complaints alleging the drug caused patients to develop pancreatitis and thyroid cancer, continue to mount in courts throughout the U.S. According to court records, the U.S. Judicial Panel on Multidistrict Litigation (JPML) is currently considering a proposal to consolidate all federal Januvia lawsuits, as well as claims involving similar diabetes drugs in the same incretin mimetics class, in a single federal court for pretrial proceedings. On April 29th, 2013, Merck & Co., the maker of Januvia, voiced support for the establishment of a multidistrict litigation for all federal claims involving the drug. However, the company is seeking to have the litigation limited to allegations that use of incretin mimetics, including Januvia, caused pancreatic cancer. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, JPML)

“We agree that the establishment of a consolidated litigation would allow claims involving incretin mimetics, including Januvia lawsuits, to proceed efficiently, ” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Januvia lawsuit consultations to victims of pancreatic cancer, pancreatitis and thyroid cancer that may be associated with the drug.

Januvia and Pancreatic Cancer

Januvia, which mimics the action of hormones in the intestinal tract that stimulate the pancreas to produce insulin, was brought to market in 2006. In 2009, a caution regarding a potential link between Januvia and pancreatitis was added to the drug’s label after the U.S. Food & Drug Administration (FDA) became aware of 88 post-marketing cases of acute pancreatitis in patients taking the drug.* Januvia also appeared to increase the risk of pancreatic cancer and pancreatitis in a study published in 2011 in Gastroenterology. Two cases of thyroid cancer were also reported in the patients who took Januvia. **

In March 2013, the FDA said it had begun investigating incretin mimetics, including Januvia, after results from an unpublished study indicated these medications might cause pre-cancerous changes in the pancreas. Most recently, a report published June 10th in the British Medical Journal revealed previously unpublished data that indicated the manufacturers of incretin mimetics may have downplayed the drugs’ potential to harm the pancreas.***

Court records indicate that more than 50 product liability claims involving incretin mimetics, including Januvia pancreatic cancer lawsuits, have been filed in federal courts around the country. The JPML will hear Oral Arguments on the possible consolidation of those claims on July 25th.

Patients who have developed pancreatic cancer, thyroid cancer or pancreatitis allegedly due to Januvia may be entitled to compensation for medical bills, lost wages, pain and suffering and more. To learn more about filing a Januvia lawsuit, please visit Bernstein Liebhard LLP’s website. For more information, please call 800-511-5092.

*fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm183800.htmSeptember 25, 2009
**gastrojournal.org/article/S0016-5085%2811%2900172-7/abstract, Gastroenterology, February 21, 2011
***bmj.com/open-data/incretin#alternate; BMJ, June 10, 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:

Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.januvialawsuit2013.com/

Read the full story at http://www.prweb.com/releases/januvia-pancreatic-cancer/januvia-lawsuit/prweb10925641.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Federal Byetta, Victoza, Januvia Lawsuits Could See Consolidation This Month, Rottenstein Law Group LLP Reports
2. Rottenstein Law Group LLP Acknowledges BMJ Study of Risks of Byetta, Januvia
3. New analysis shows that patients with Type 2 diabetes and mild renal impairment had similar improvement in blood sugar control and experienced less hypoglycemia with JANUVIA (sitagliptin) compared to sulfonylurea
4. DrugRisk Update: Panel To Decide Fate of Januvia Lawsuits Next Week
5. Januvia Pancreatic Cancer Lawsuits: Bernstein Liebhard LLP Comments on Medical Journal’s Investigation of Incretin Mimetics
6. Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics
7. Rottenstein Law Group LLP Comments on Drugmakers’ Cooperation With Safety Review of Byetta, Januvia, Victoza
8. Januvia Lawsuit News: Rottenstein Law Group LLP Comments on Doctor’s Doubts About Januvia
9. Januvia Lawsuits Consultations Now Offered by the Berman Law Group, Januvia Lawyers and Compensation Experts
10. DrugRisk Adds New Pancreatic Cancer Warning for Diabetes Drug Januvia
11. Pancreatic Cancer Correlation to Type 2 Diabetes Drugs Januvia and Byetta, New Studies Find Possible Connection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... Rollon Skin ... anti-aging skincare solutions, recently announced the launch of two new skincare products, ... yet effective alternative to expensive plastic surgery or in-patient cosmetic dermatological procedures. , ...
(Date:8/18/2017)... ... ... “Steve the Snake”: an entertaining and moral-based short story about an unkind ... Harold Flash Haskins Jr., a husband, father and grandfather who served as a U.S. ... moral-based short stories for children and teens. My goal is to teach kids to ...
(Date:8/17/2017)... Waltham, Mass (PRWEB) , ... August 17, 2017 ... ... high use by health care organizations and considered extremely effective, very effective, or ... “Leading Physicians and Physician Leadership”. , NEJM Catalyst Insights Reports are based on ...
(Date:8/17/2017)... ... 17, 2017 , ... Industry CEOs, life science leaders, influential ... This off-the-record networking forum of the Boston Biotech Conference series will be held ... leaders and decision makers will discuss issues facing the development of anti-infective, antiviral, ...
(Date:8/17/2017)... City, Utah (PRWEB) , ... August 17, 2017 , ... ... share how to efficiently and effectively grow a dental practice in a competitive market ... hours of dental C.E. that could just transform you and your practice.” says Daniel ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... , Aug. 2, 2017 Fenita ... Who as a Pinnacle Lifetime Professional in the ... Account Manager at Turing Pharmaceuticals, AG. Her skills ... and relationship building.                ... than 25 years of experience as a highly ...
(Date:8/1/2017)... --  CerSci Therapeutics , a non-opioid drug development firm ... received notice from the National Institute on Drug Abuse ... it has been awarded a Direct-to-Phase II Small Business ... with an additional $1,000,000 to follow in 2018. These ... their lead non-opioid drug candidate CT-044 to the Food ...
(Date:7/28/2017)... -- Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today announced ... 30, 2017, and updated its financial outlook for fiscal ... the fiscal third quarter, Hill-Rom reported earnings of $0.09 ... in the prior-year period. These results reflect after-tax special ... primarily related to the non-cash write-down of assets associated ...
Breaking Medicine Technology: